Nyrada Inc. (ASX:NYR)

20.5¢

right-arrow Created with Sketch. 0.005 (2.5%)
MCAP $31.98M
Last trade 16.10pm 28/01/2022 20mins delayed

Latest Announcements

21/01/2022 Price SensitivePSNYRNyrada Inc.
17/01/2022NYRNyrada Inc.
17/01/2022NYRNyrada Inc.
17/01/2022NYRNyrada Inc.
17/01/2022NYRNyrada Inc.
17/01/2022NYRNyrada Inc.
17/01/2022NYRNyrada Inc.
17/01/2022NYRNyrada Inc.

Company Overview

Nyrada Inc is an Australia-based drug development company. The Company focuses on development of small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. Its drug development programs include a proprotein convertase subtilisin/kexin type nine (PCSK9) inhibitor for the treatment of high blood low-density lipoprotein (LDL)-cholesterol levels in patients poorly responsive to or unable to take statin drugs. It develops a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury. The Company also develops a drug to treat pain associated with peripheral nerve damage and autoimmune diseases such as psoriasis.

NYR in the news

Nyrada (NYR) receives a $1.3 million research and development rebateThe rebate relates…
Biotechnology company Nyrada (NYR) has appointed Charles River Laboratories to conduct preclinical…
Nyrada (NYR) receives a new US patent for its cholesterol lowering programThe…
Results from a preclinical trial of Nyrada’s (NYR) molecule, PCSK9i, show it’s…

Search Previous Announcements